Detection Of Diabetic Retinopathy Using Convolutional Neural Network

Dhivan T [1],Illayaraja R[2] ,Suresh Gopi B[3], Dr Mythili S[4]
[1, 2, 3] Dept of Biomedical Engineering
[4]Professor, Dept of Biomedical Engineering
[1, 2, 3, 4] PSNA College of Engineering and Technology, Dindigul.

Abstract- *Diabetic Retinopathy (DR) is a leading cause of vision loss globally, particularly among individuals with long-standing diabetes. Early detection and grading of DR are vital to prevent irreversible blindness. This project presents an end-to-end, AI-powered web application for the automatic classification of Diabetic Retinopathy from fundus images using a Convolutional Neural Network (CNN) deployed via a FastAPI framework. The trained model, based on TensorFlow, classifies input retinal images into five categories: No DR, Mild, Moderate, Severe, and Proliferative DR. The dataset used to train the model was sourced from Kaggle, consisting of high-resolution retina images labeled by clinical experts. The application provides a modern, responsive frontend using HTML, CSS, and JavaScript, allowing users to upload retinal images and receive real-time diagnostic predictions. The backend model preprocesses uploaded images using OpenCV and NumPy, resizing them to 224x224 pixels, normalizing them, and feeding them into the trained CNN model. The system aims to serve as a fast, reliable, and accessible tool to assist ophthalmologists and healthcare professionals in screening for DR. It can also act as a valuable aid in regions with limited access to medical infrastructure, where regular eye checkups are not always feasible. Through this project, we demonstrate the real-world application of AI and web development for medical diagnostics, bridging the gap between complex deep learning models and user-friendly interfaces.*

Keywords- Diabetic Retinopathy(DR), Convolutional Neural Network (CNN), HyperText Markup Language, Cascading Style Sheets.

I. INTRODUCTION

Diabetic Retinopathy(DR) is a chronic, progressive eye disease and one of the most common complications of diabetes mellitus, representing a major cause of vision impairment and blindness in working-age adults globally. It occurs due to long-term effects of high blood sugar levels, which gradually damage the tiny blood vessels that supply the retina, which is the light-sensitive layer that present at the back of the eye that’s essential for vision. Over time, this vascular damage can lead to various structural and functional changes in the retina, including leakage of blood or fluid, tissue swelling, and abnormal blood vessel growth. These changes disrupt the normal functioning of the retina, which leads to symptoms such as blurred vision, floaters, and, in severe cases, complete loss of sight.

Diabetic Retinopathy typically develops silently and can progress without noticeable symptoms until significant damage has occurred, making regular eye examinations vital for individuals with diabetes. The disease progresses through well-defined stages, ranging from mild non-proliferative diabetic retinopathy to advanced proliferative diabetic retinopathy, where the risk of vision-threatening complications increases substantially. Additionally, diabetic macular edemais a swelling in the central part of the retina, which can occur at any stage and is a major cause of vision loss. Risk factors such as poor blood glucose control, hypertension, high cholesterol, and the duration of diabetes significantly influence the onset and severity of the disease.

Diabetic Retinopathy(DR) is a progressive eye disease caused by chronic hyperglycemia in people with diabetes mellitus. It affects the small blood vessels of the retina, leading to microvascular damage and resulting in various structural and functional retinal abnormalities. The condition is typically categorized into two main types based on severity and progression: common methods include:

1. Non-Proliferative Diabetic Retinopathy (NPDR)
2. Proliferative Diabetic Retinopathy (PDR).
3. Diabetic Macular Edema (DME)

Non-Proliferative Diabetic Retinopathy (NPDR) is a progressive eye disease caused by damage to the blood vessels in the retina, typically as a result of prolonged high blood sugar levels due to uncontrolled diabetes. This stage is classified as the earliest and most common form of diabetic retinopathy, occurring in a majority of people with diabetes. Over time, high glucose levels in the bloodstream cause the walls of small blood vessels in the retina to weaken, leading to the formation of microaneurysms, tiny bulges in the capillaries that can leak fluid into the surrounding tissues. As the condition progresses, more vascular changes occur, including retinal hemorrhages (bleeding in the retina) and the formation of exudates, which are deposits of lipids and proteins that accumulate due to leakage from damaged vessels.

In moderate to severe cases of NPDR, intraretinal microvascular abnormalities (IRMAs) develop, where blood vessels within the retina become distorted, affecting blood flow. Retinal ischemia, or the inadequate supply of oxygen to retinal tissue, becomes a significant feature of advanced NPDR. This ischemia triggers the release of vascular endothelial growth factor (VEGF), which can cause the growth of new, fragile blood vessels, increasing the likelihood of progression to Proliferative Diabetic Retinopathy (PDR).

One of the hallmark features of NPDR is macular edema, which occurs when the leaking blood vessels cause fluid to accumulate in the macula, the central part of the retina responsible for sharp vision. Macular edema is a leading cause of vision impairment in people with diabetes and is the most common complication associated with NPDR. The severity of NPDR is categorized into three stages: mild, moderate, and severe. In the mild stage, only microaneurysms are observed, and there are typically no noticeable symptoms.

Moderate NPDR is characterized by more widespread retinal hemorrhages, exudates, and areas of retinal ischemia. In severe NPDR, extensive retinal ischemia and capillary non-perfusion are observed, significantly increasing the risk of progression to PDR, where new blood vessels form, often leading to vision-threatening complications such as retinal detachment or vitreous hemorrhage.

Although the early stages of NPDR may not cause noticeable vision changes, patients may experience blurred vision, fluctuating vision, and, in some cases, difficulty with color perception or night vision. The lack of symptoms in the initial stages makes regular screening for diabetic retinopathy essential for those with diabetes, especially as it can be asymptomatic until the later stages. Early detection through routine eye exams, including fundus photography, fluorescein angiography, and optical coherence tomography (OCT), allows for close monitoring and intervention before significant vision loss occurs.

Fundus photography provides high-resolution images of the retina, revealing changes such as microaneurysms and hemorrhages, while fluorescein angiography uses a dye to highlight areas of leakage, helping to assess the extent of retinal damage. OCT provides cross-sectional images of the retina, allowing for the detection of macular edema and other retinal changes.

Managing NPDR primarily involves controlling the underlying causes of the disease, such as blood glucose levels, blood pressure, and cholesterol. Strict glycemic control is essential for slowing the progression of retinopathy and preventing further damage to the retinal blood vessels. Blood pressure management is equally important, as hypertension accelerates retinal damage. In cases where macular edema or severe NPDR is diagnosed, treatment options may include laser therapy (such as focal laser photocoagulation) to reduce leakage from damaged blood vessels, and intravitreal injections of anti-VEGF drugs to decrease fluid buildup in the retina and prevent further blood vessel formation. Corticosteroid injections may also be used in some cases to reduce inflammation and macular edema.

Proliferative Diabetic Retinopathy (PDR), the most severe form of diabetic retinopathy and occurs as a consequence of prolonged uncontrolled diabetes. As the condition progresses, the blood vessels in the retina become severely damaged, causing ischemia, or lack of blood flow, to the retinal tissues. In response to this oxygen deficiency, the retina attempts to restore its blood supply by producing Vascular Endothelial Growth Factor (VEGF), a signaling protein that stimulates the growth of new, but fragile and abnormal, blood vessels. These new blood vessels, called neovascularization, are particularly prone to leakage and bleeding.

The abnormal blood vessels that develop in PDR are often found on the surface of the retina or in the vitreous body, a gel-like substance in the eye. Because these vessels are weak and prone to rupture, they can cause vitreous hemorrhages, a condition where blood leaks into the vitreous, leading to sudden, severe vision loss or floating spots in the vision. Additionally, the formation of scar tissue in response to the abnormal blood vessels can result in tractional retinal detachment, where the retina becomes pulled away from its normal position. This can cause permanent vision loss if left untreated.

Diabetic Macular Edema (DME), a serious complication of diabetes that affects the macula, the part of the retina responsible for central vision. It occurs when high blood sugar levels cause damage to the small blood vessels in the retina, leading to leakage of fluid and proteins into the surrounding retinal tissue. The macula, which is critical for detailed and sharp vision, becomes swollen as a result of this fluid accumulation, causing vision distortion and blurring. DME is a common cause of vision loss in diabetic patients and is considered a major threat to visual acuity if not addressed in time. In the early stages, patients may not experience any symptoms, making regular eye exams essential for early detection. As the disease progresses, patients may notice visual changes, including difficulty reading, problems with color perception, and blurred vision, especially when trying to focus on fine details or perform tasks requiring high visual acuity.

The underlying cause of DME is retinal ischemia, a condition in which the blood supply to the retina is insufficient. This ischemia leads to the release of Vascular Endothelial Growth Factor (VEGF), a signaling molecule that promotes the growth of abnormal blood vessels. These newly formed vessels are fragile and leak fluid into the surrounding retinal tissue, causing the macula to swell. This leakage leads to the formation of hard exudates, yellowish deposits that accumulate in the retina as a result of the leakage of lipid material. In addition to these exudates, microaneurysms—small, swollen blood vessels that can rupture and leak fluid—are often observed in patients with DME.

Advanced diagnostic imaging techniques such as Optical Coherence Tomography (OCT), fluorescein angiography, and fundus photography are essential for diagnosing and monitoring DME. OCT is particularly useful in providing high-resolution cross-sectional images of the retina, allowing for precise measurements of retinal thickness and identification of areas of fluid accumulation in the macula. Fluorescein angiography, in which a dye is injected into the bloodstream, highlights areas of leakage and can help determine the extent of vascular damage and identify potential treatment targets. Fundus photography captures detailed images of the retina, enabling the physician to track disease progression and assess the effectiveness of treatment interventions over time.

The treatment of DME has evolved considerably with the advent of anti-VEGF therapy, which has become the standard treatment for many patients. Anti-VEGF injections, such as ranibizumab, bevacizumab, and aflibercept, work by blocking the action of VEGF, thereby reducing the growth of abnormal blood vessels and decreasing fluid leakage in the macula. These injections have been shown to significantly improve visual acuity and reduce macular swelling in many patients. In some cases, a steroid injection (e.g., triamcinolone) may be used to reduce inflammation and fluid accumulation, although steroids are associated with potential side effects, including elevated intraocular pressure and cataract formation, which must be carefully monitored. Laser photocoagulation remains a treatment option for focal DME, particularly when fluid leakage is localized. In this procedure, a laser is used to target and seal leaking blood vessels, preventing further fluid leakage and reducing macular swelling. However, laser therapy is typically reserved for specific cases where other treatments have not been effective.

In addition to local treatments for DME, managing the underlying diabetes is crucial for preventing the progression of the disease. Tight blood sugar control is essential for reducing the risk of diabetic complications, including DME. Maintaining normal blood pressure and cholesterol levels is also important for minimizing the risk of further damage to the retinal blood vessels. Lifestyle changes such as adopting a healthy diet, regular exercise, and weight management can also help in controlling blood sugar and improving overall health. Regular eye examinations are necessary for individuals with diabetes, as DME can often develop silently, without obvious symptoms. Timely intervention and consistent monitoring are key to preventing severe vision loss.

Although DME can lead to significant vision impairment, modern treatments offer hope for preserving and improving vision, especially when the condition is diagnosed early. Patients with DME who undergo appropriate treatment and management of their diabetes can experience improved visual outcomes and reduced risk of permanent vision loss. However, if left untreated, DME can lead to irreversible damage to the macula, potentially resulting in blindness. As such, it is critical for diabetic patients to adhere to regular eye check-ups and seek prompt treatment if any signs of macular edema or other diabetic eye complications arise.The continued advancement of treatment options and ongoing research into new therapies offer the potential for even better outcomes in the management of DME in the future.

The diagnosis of Diabetic Retinopathy (DR) involves a combination of patient history, clinical evaluation, and advanced imaging techniques, aimed at identifying early retinal changes before they result in vision loss. Routine eye examinations are essential, particularly for individuals with long-standing diabetes, as DR can remain asymptomatic in its early stages. The cornerstone of DR diagnosis is a comprehensive dilated fundus examination performed by an ophthalmologist or optometrist, where the retina is evaluated for characteristic lesions such as microaneurysms, dot and blot hemorrhages, hard exudates, cotton wool spots, venous beading, and neovascularization. Fundus photography provides high-resolution images of the retina and is widely used for documentation and longitudinal monitoring. Optical Coherence Tomography (OCT) is a non-invasive imaging technique that provides cross-sectional images of the retina, allowing precise detection of macular edema, retinal thickening, and structural abnormalities, making it particularly useful in diagnosing Diabetic Macular Edema (DME).

Fluorescein angiography, another critical diagnostic tool, involves the intravenous injection of fluorescein dye followed by sequential retinal imaging, revealing details about retinal blood flow, capillary non-perfusion, and areas of leakage, thus helping to stage DR and guide laser therapy. OCT angiography, a newer advancement, provides detailed maps of retinal and choroidal vasculature without the need for dye injection, offering a safer and faster alternative for vascular assessment. Visual acuity testing and intraocular pressure measurement are also integral to the diagnostic process, especially to rule out other comorbid eye conditions such as glaucoma and cataracts. Early diagnosis is enhanced through AI-driven software tools capable of detecting DR from fundus images with high accuracy, facilitating large-scale screening and teleophthalmology programs, particularly in underserved populations.

Risk stratification and staging, based on the International Clinical Diabetic Retinopathy Disease Severity Scale, are crucial in determining appropriate follow-up intervals and intervention strategies. Ultimately, timely and accurate diagnosis of DR enables early treatment, reduces the risk of irreversible vision loss, and improves overall outcomes, reinforcing the importance of regular eye care in all diabetic patients.

II. LITERATURE SURVEY

Diabetic retinopathy (DR) can begin with subclinical neurovascular damage. Early signs include retinal thinning, visual function changes, vascular abnormalities, and elevated biomarkers. Emerging imaging and molecular techniques show promise for early detection, pending human validation[1].Diabetic retinopathy, caused by retinal microvascular damage from diabetes, can lead to blindness if untreated. This paper reviews automated techniques for detecting microaneurysms, hemorrhages, exudates, and blood vessels to diagnose both nonproliferative and proliferative DR. It also discusses experimental findings to aid researchers and developers in the field[2].This study compares two DR detection algorithms—EyeCheck and Challenge2009—on 16,670 fundus image sets. Both performed well, with AUCs of 0.839 and 0.821, nearing clinical accuracy. Combined detection reached an AUC of 0.86, suggesting algorithm maturity[3].A neural network was trained to detect diabetic retinopathy in fundus images, achieving 88.4% sensitivity and 83.5% specificity. It showed high accuracy for vessels, exudates, and hemorrhages. The system could support ophthalmologists in DR screening[4].A neural network-based system was developed to detect diabetic retinopathy in retinal images. At 94.8% sensitivity and 52.8% specificity, it missed no sight-threatening cases and could reduce human grading by one-third. This shows strong potential for screening use[5].This study applies CNNs to color fundus images for diabetic retinopathy staging, achieving 95% validation sensitivity. Preprocessing and expert-verified labels improved detection of subtle features. Transfer learning with GoogLeNet and AlexNet enhanced classification accuracy across multiple staging levels[6].A Review on Datasets, Methods and Evaluation Metrics: This paper reviews the automated detection of Diabetic Retinopathy (DR) using artificial intelligence, highlighting retinal datasets, detection methods, and performance metrics. It contrasts manual detection, which is time-consuming and costly, with AI-based systems offering more efficient solutions. The paper also provides future directions to address research challenges in DR detection[7].This study develops an automated system for detecting NPDR features in retinal images, achieving high sensitivity and specificity for exudates (88.5% and 99.7%) and haemorrhages/microaneurysms (77.5% and 88.7%). The results demonstrate the potential for automated NPDR screening[8].This study uses DenseNet-169, a deep learning model, for early detection of Diabetic Retinopathy (DR) from fundus images, classifying them into severity levels. The model achieved 90% accuracy, with a regression model reaching 78% accuracy. The goal is to develop a robust automated DR detection system[9].This review summarizes recent developments in automated diabetic retinopathy (DR) detection using machine learning, focusing on CNNs, ANNs, and hybrid models. It analyzes 150 research articles published in the last five years, providing a comprehensive overview of DR detection methods. The paper aims to enhance understanding of AI-based approaches for DR screening[10].Diabetic Retinopathy (DR), a vision-threatening complication of diabetes, requires early detection for effective treatment. Manual diagnosis is time-consuming and costly, while AI-powered systems offer faster, more efficient screening. This article reviews current DR detection methods and highlights future research directions[11].Diabetic Retinopathy (DR), a major complication of long-term diabetes, can lead to blindness. This study evaluates 26 deep learning models for DR detection from fundus images, identifying EfficientNetB4 as the most accurate and reliable. It achieved 99.37% training and 79.11% validation accuracy on the EyePACSdataset[12].Diabetic Retinopathy can cause blindness if not detected early. This study uses a deep learning model with PCA for dimensionality reduction and Harris Hawks Optimization for improved feature extraction. Tested on the UCI dataset, the model shows superior accuracy, specificity, precision, and recall over existing methods[13].A deep ensemble model using improved Inception-v4 was developed to detect Diabetic Retinopathy (DR) and Diabetic Macular Edema (DMO) from retinal fundus images. On a dataset of 8739 images, the model outperformed or matched ophthalmologists with high sensitivity and specificity. It also generalized well on the Messidor-2 dataset, showing strong potential for use in DR/DMO screening programs[14].This study proposes an automated technique for detecting diabetic retinopathy using fundus images by identifying exudates and microaneurysms. Severity grading is based on exudates' distance from the macula and microaneurysm count. Machine learning models achieved high accuracy, with SVM/KNN reaching 92.1% and decision trees 99.9%[15].This study presents a three-step system for detecting diabetic retinopathy using OCT images. It segments retinal layers, extracts 3D features, and classifies images using backpropagation neural networks. The method achieved 96.81% accuracy, highlighting its effectiveness[16].This study proposes a transfer learning-based ensemble model for automated diabetic retinopathy detection using fundus images. Six CNN models were trained, with preprocessing applied to enhance accuracy and efficiency. The model achieved up to 98% accuracy, outperforming existing methods[17]. This article provides a comprehensive review of automated Diabetic Retinopathy (DR) detection using deep learning and image processing. It covers causes, datasets, lesion segmentation, and model optimization. The study aims to assist researchers, clinicians, and patients with valuable insights[18].This study introduces a CNN-based deep learning model for early and late-stage Diabetic Retinopathy (DR) detection using retinal images. The model classifies images into DR or non-DR categories. It achieved up to 96% accuracy, enhancing screening efficiency[19].This study presents an automated method for detecting Diabetic Retinopathy (DR) using Optical Coherence Tomography (OCT) images. It segments seven retinal layers via a Graph-Cut algorithm and extracts features like layer thickness and neovascularization. These features effectively differentiate between healthy and DR-affected eyes[20].Diabetes, a metabolic disorder, leads to a retinal complication known as Diabetic Retinopathy (DR), one of the leading causes of blindness worldwide. DR often presents no clear symptoms in its early stages, making timely identification and diagnosis challenging[21].Diabetic Retinopathy is a major cause of vision loss in diabetic patients due to retinal blood vessel damage. This study proposes an automated detection system using image processing and machine learning on retinal images from DIARETDB0 and DIARETDB1. Among the tested classifiers, Simple Tree achieves the highest accuracy of 88.6%, showing promise for efficient and accurate DR detection[22].Diabetic Retinopathy is a retinal disease caused by chronic diabetes, where early detection is crucial for preventing vision loss. Using the APTOS 2019 Blindness Detection dataset, a VGG-16 based CNN model was trained on 3668 retinal images and tested on 1728 unseen samples, achieving 74.58% accuracy. The model, optimized with ADAM and trained using categorical cross-entropy, outputs severity on a scale of 0–4 and aids in early, automated diagnosis[23].Diabetic Retinopathy (DR), a leading cause of blindness, requires early and efficient diagnosis to prevent vision loss. This study presents a lightweight custom CNN model using OCT images, aimed at integration within IoT environments for remote DR screening. Leveraging MobileNet and transfer learning, the model achieved 80% accuracy, 85% precision, and 80.5% recall, demonstrating its potential for scalable, real-time healthcare delivery[24].This study uses deep learning to detect the severity of diabetic retinopathy and the risk of macular edema using retina images from the IDRiD dataset. Preprocessing techniques like BCC, CJ, and CLAHE were applied to improve image quality. ResNet50 achieved the highest accuracy for severity detection, while UNet effectively segmented disease patterns, showing that image enhancement improves model performance[25].Diabetic retinopathy is a diabetes-related eye disease that can cause blindness if untreated. This study proposes a machine learning-based system using neural networks to detect and classify retinal abnormalities like exudates, hemorrhages, and microaneurysms for early diagnosis and treatment[26].Diabetic Retinopathy (DR) is a leading cause of vision loss, and early detection is crucial. This review highlights recent AI-based approaches, including machine and deep learning, used for DR detection, grading, and lesion segmentation from fundus and OCT images. A total of 114 studies and 43 major datasets are summarized, showcasing the potential of AI in enhancing DR diagnosis[27].

III. PROPOSED METHODOLOGY

Diabetic Retinopathy (DR) is one of the most common and severe complications arising from prolonged diabetes mellitus, and it remains a leading cause of blindness in working-age adults worldwide. As the global prevalence of diabetes continues to increase, particularly in developing countries, the burden of diabetic retinopathy has grown substantially. Early diagnosis and timely intervention are critical to preventing irreversible vision loss, yet regular retinal screening remains inaccessible for many due to a shortage of trained ophthalmologists and diagnostic infrastructure, especially in remote and under-resourced regions. In this context, the application of Artificial Intelligence (AI) and deep learning technologies to automate the screening and diagnosis of diabetic retinopathy has emerged as a promising and transformative solution. By harnessing the power of AI, healthcare providers can ensure early detection, reduce human error, and improve the speed and scalability of diagnostic services.

This project presents the design and implementation of an AI-based web application for classifying diabetic retinopathy using Convolutional Neural Networks (CNNs). The core objective of the project is to develop an automated and accessible system that can analyze retinal fundus images and classify them into the appropriate stage of diabetic retinopathy, including No DR, Mild, Moderate, Severe, and Proliferative DR. Through the application of a supervised deep learning approach, the system is trained on a publicly available retinal image dataset, which includes pre-labeled examples of various stages of DR. The use of CNNs, known for their high accuracy in image recognition tasks, enables the model to learn complex patterns and minute features in retinal images, such as microaneurysms, hemorrhages, and neovascularization.

The project workflow involves several key phases: image preprocessing, data augmentation, model building and training, and deployment. Image preprocessing ensures that the raw retinal images are resized, normalized, and enhanced for better model input. Data augmentation techniques such as rotation, flipping, and contrast adjustments are applied to increase the diversity of the dataset and prevent overfitting. A custom CNN model is designed using TensorFlow, optimized with appropriate layers and hyperparameters to maximize classification accuracy. The trained model is evaluated using precision, recall, and accuracy to ensure robustness and reliability. Finally, a user-friendly web application is developed using FastAPI to provide a seamless interface where users can upload fundus images and receive instant diagnostic predictions.

The significance of this project lies not only in its technical implementation but also in its potential real-world impact. An accurate, AI-driven DR classification system can assist general practitioners, optometrists, and healthcare workers in identifying high-risk patients and referring them for further ophthalmologic evaluation. This can alleviate the burden on healthcare systems, reduce patient wait times, and ultimately help in preserving vision for millions.The integration of this technology into telemedicine platforms can further extend its reach, enabling proactive diabetic eye care in rural and underserved areas.In summary, this project aims to bridge the gap between technological advancement and clinical application by developing a reliable, efficient, and scalable solution for diabetic retinopathy classification. It serves as an example of how biomedical engineering, artificial intelligence, and software development can converge to address critical healthcare challenges and improve patient outcomes through innovative digital tools.



The development of the Diabetic Retinopathy (DR) classification system began with the acquisition of a high-quality dataset. For this project, the dataset was sourced from the Diabetic Retinopathy Detection challenge hosted on Kaggle. Approximately 3000 datasets are collected based on both genders, Diabetic retinopathy is most commonly diagnosed in adults aged 40 years and older. This dataset comprises thousands of high-resolution retinal fundus images, each labeled by medical experts with a corresponding grade that represents the severity of Diabetic Retinopathy. The grades range from 0 to 4, where 0 indicates no DR and 4 represents the most severe form, Proliferative DR. These images reflect a broad spectrum of pathological conditions, enabling the model to learn from a diverse and realistic representation of the disease. The dataset was split into training, validation, and test subsets to ensure unbiased performance evaluation and robust learning. Proper care was taken to balance the dataset through augmentation to address class imbalance issues, which are common in medical image classification problems. Preprocessing plays a vital role in ensuring the quality and uniformity of input data, especially when dealing with medical images that often suffer from variations in lighting, focus, and scale. In this project, preprocessing involved several key steps. Initially, all images were resized to a standard dimension of 224x224 pixels to conform to the input shape required by the convolutional neural network. Following this, pixel values were normalized to fall within the [0, 1] range, which helps in stabilizing the training process and improving convergence speed. Additional preprocessing methods included color space adjustments, application of Gaussian blur to reduce image noise, and histogram equalization to enhance contrast. These steps collectively improve the model's ability to focus on relevant features, such as microaneurysms, hemorrhages, and exudates, which are crucial for accurate DR classification. Furthermore, data augmentation techniques like horizontal flipping, rotation, and zoom were implemented to artificially expand the dataset, which helps reduce overfitting and improve generalization.To improve the performance and generalization of the diabetic retinopathy classification model, data augmentation techniques were applied to the retinal fundus image dataset. Using TensorFlow's ImageDataGenerator, real-time augmentation was performed during training. The techniques included horizontal and vertical flipping, random rotation, zooming, brightness adjustment, and shifting. These transformations helped address class imbalance and reduced the risk of overfitting. Augmentation ensured that the model learned robust features by being exposed to diverse variations of the input images, which is critical for detecting subtle signs of diabetic retinopathy.The core of the system is a Convolutional Neural Network (CNN) developed using the TensorFlow and Keras libraries. The model architecture was designed with a series of convolutional layers followed by max-pooling operations, which are effective in extracting and compressing important visual features. The feature maps are then passed through a flattening layer and multiple dense (fully connected) layers, culminating in a softmax output layer that classifies the image into one of the five DR categories. ReLU activation functions were used throughout the hidden layers, and dropout layers were inserted to prevent overfitting. The training was conducted using the Adam optimizer and categorical cross-entropy loss function. The learning rate and batch size were carefully tuned to optimize training stability and speed. The model was trained over multiple epochs with early stopping criteria based on validation loss to avoid overtraining. The training phase also involved the use of callbacks for checkpointing the best model and logging the performance metrics for visualization using TensorBoard. Once the model was trained, its performance was evaluated on the validation and test datasets to ensure that it generalized well to unseen images. Evaluation metrics included Accuracy measures the overall correctness of the model by calculating the ratio of correctly predicted cases (both true positives and true negatives) to the total number of cases, but it may be misleading in imbalanced datasets. Precision focuses on the quality of positive predictions by evaluating how many of the predicted positive cases were actually correct, which helps reduce false alarms. Recall, also known as sensitivity, determines the model's ability to identify actual positive cases, making it critical in medical scenarios where missing a true disease case (false negative) can have serious consequences. F1-score is the harmonic mean of precision and recall, offering a balanced metric that is especially useful when both false positives and false negatives carry significant risk.

In the context of diabetic retinopathy detection, these metrics collectively provide a comprehensive understanding of the model's performance across all stages of the disease. These metrics provided a comprehensive view of the model's ability to correctly classify images across all severity levels of DR. The confusion matrix was particularly useful in identifying misclassifications between adjacent classes, such as Mild and Moderate DR, which are more challenging to distinguish.

The results revealed that the model performed exceptionally well in identifying the extremes (No DR and Proliferative DR), but had slightly lower precision in the middle categories. This insight led to further fine-tuning of the model and adjustments in the class weighting during training. ROC-AUC scores were also calculated to assess the model's discriminative ability across thresholds, especially important in medical diagnosis scenarios where sensitivity and specificity are critical.After the successful training of the CNN model, the next phase involved building a web-based application to make the solution accessible and easy to use. The backend of the application was developed using FastAPI, a modern Python web framework known for its speed and support for asynchronous operations. FastAPI was used to create RESTful APIs that handle image uploads, perform preprocessing, and return prediction results. The model was loaded during the server startup to avoid delays during prediction. The frontend was created using HTML5, CSS3, and JavaScript, providing a clean and responsive interface where users could upload fundus images for evaluation. Once an image is uploaded, the backend receives it, performs the necessary preprocessing steps, and feeds it into the CNN model. The prediction result is then returned in JSON format and displayed dynamically on the user interface. This integration enables real-time diagnosis and ensures a smooth user experience, making it ideal for use in both clinical and telemedicine settings.To bring the project into a usable state, the final step was deploying the complete system in a way that ensures reliability and performance. The FastAPI backend was deployed using Uvicorn, a lightning-fast ASGI server that supports asynchronous programming and enables the application to handle multiple requests simultaneously. The application was packaged into a container using Docker for portability and ease of deployment across different environments. Basic security practices were followed, including validation of uploaded files and limitation of file size to prevent misuse.

The model file was optimized using TensorFlow Lite for faster loading times and reduced memory usage. Hosting options included local deployment for demonstration and cloud-based deployment for real-world accessibility, such as using platforms like Heroku or Google Cloud Platform. The deployed application is capable of operating in real time, allowing users to upload retinal images and receive DR predictions within seconds. This smooth deployment pipeline ensured that the technical components of the model were integrated into a robust, user-friendly medical tool.

IV. RESULTS AND DISCUSSION

The trained model demonstrated promising performance in classifying Diabetic Retinopathy across five severity levels. After thorough training and validation, the model achieved an accuracy of approximately 85% on the validation set. Precision and recall were particularly high for classes like “No DR” and “Proliferative DR,” indicating the model’s strength in identifying both extremes of the disease spectrum. However, the model faced minor challenges in distinguishing between intermediate classes such as Mild and Moderate DR, which can sometimes appear similar due to overlapping features in fundus images.The integration of the trained model with the FastAPI framework provided a seamless user experience. Users can upload images and receive predictions in real time (usually under 1 second per image), which validates the system's speed and responsiveness. The frontend's intuitive interface with visual feedback (image preview and styled prediction results) improves user engagement and usability.

Furthermore, the model’s robustness was evaluated using multiple unseen test images, and results showed consistent classification with high confidence scores. However, it's important to acknowledge that the performance depends heavily on image quality. Poor lighting or blurry images reduce prediction confidence. The app performed best with well-lit, centered fundus photographs.

Despite the good performance, further improvements can be made by training on more diverse datasets and incorporating additional data augmentation techniques. Overall, the system has shown strong potential as a clinical screening aid or second-opinion tool for DR diagnosis.

V. CONCLUSION AND FUTURE SCOPE

AI-driven diagnostic systems represent a powerful advancement in modern healthcare, particularly in the early detection and classification of diabetic retinopathy. By leveraging convolutional neural networks trained on retinal fundus images, it becomes possible to achieve high accuracy in identifying disease stages. When integrated with a user-friendly web interface, such systems can offer real-time analysis, improving screening efficiency and accessibility. Metrics like precision, recall, and F1-score confirm the reliability and performance of these AI solutions, reinforcing their role as effective tools in clinical decision-making. Their deployment demonstrates the potential of artificial intelligence to support timely diagnoses, reduce workload on specialists, and enhance patient outcomes.

Looking ahead, several enhancements can further elevate system capabilities. Employing advanced architectures like EfficientNet or Vision Transformers may improve sensitivity, especially for early or mild cases where retinal changes are subtle. Enriching the dataset with diverse images from different imaging devices and populations can enhance robustness and reduce bias. Explainable AI techniques such as Grad-CAM offer valuable visual insights, promoting trust and transparency for healthcare professionals. Multimodal data integration—combining imaging with medical history—can provide a more holistic diagnostic view.

Transitioning to cloud-based deployment ensures broader reach, while a mobile-friendly version increases accessibility in low-resource settings. Supporting multiple languages and integrating with electronic health records can streamline clinical adoption. Additionally, implementing a continuous learning loop by retraining models with newly labeled data ensures long-term accuracy and adaptability in real-world environments.

In essence, combining deep learning, medical imaging, and intelligent deployment strategies opens new pathways for scalable, efficient, and trustworthy diagnostic tools in ophthalmology and beyond.

REFERENCES

[1] Safi, H., Safi, S., Hafezi-Moghadam, A., &Ahmadieh, H. (2018). Early detection of diabetic retinopathy. Survey of ophthalmology, 63(5), 601-608.
[2] Amin, J., Sharif, M., & Yasmin, M. (2016). A review on recent developments for detection of diabetic retinopathy. Scientifica, 2016(1), 6838976.

[3] Abràmoff, M. D., Reinhardt, J. M., Russell, S. R., Folk, J. C., Mahajan, V. B., Niemeijer, M., & Quellec, G. (2010). Automated early detection of diabetic retinopathy. Ophthalmology, 117(6), 1147-1154.

[4] Gardner, G. G., Keating, D., Williamson, T. H., & Elliott, A. T. (1996). Automatic detection of diabetic retinopathy using an artificial neural network: a screening tool. British journal of Ophthalmology, 80(11), 940-944.

[5] Usher, D., Dumskyj, M., Himaga, M., Williamson, T. H., Nussey, S., & Boyce, J. (2004). Automated detection of diabetic retinopathy in digital retinal images: a tool for diabetic retinopathy screening. Diabetic Medicine, 21(1), 84-90.

[6] Lam, C., Yi, D., Guo, M., & Lindsey, T. (2018). Automated detection of diabetic retinopathy using deep learning. AMIA summits on translational science proceedings, 2018, 147.

[7] Mateen, M., Wen, J., Hassan, M., Nasrullah, N., Sun, S., & Hayat, S. (2020). Automatic detection of diabetic retinopathy: a review on datasets, methods and evaluation metrics. IEEE Access, 8, 48784-48811.

[8] Sinthanayothin, C., Boyce, J. F., Williamson, T. H., Cook, H. L., Mensah, E., Lal, S., & Usher, D. (2002). Automated detection of diabetic retinopathy on digital fundus images. Diabetic medicine, 19(2), 105-112.

[9] Mushtaq, G., & Siddiqui, F. (2021, February). Detection of diabetic retinopathy using deep learning methodology. In IOP conference series: materials science and engineering (Vol. 1070, No. 1, p. 012049). IOP Publishing.

[10] Selvachandran, G., Quek, S. G., Paramesran, R., Ding, W., & Son, L. H. (2023). Developments in the detection of diabetic retinopathy: a state-of-the-art review of computer-aided diagnosis and machine learning methods. Artificial intelligence review, 56(2), 915-964.

[11] Bilal, A., Sun, G., & Mazhar, S. (2021). Survey on recent developments in automatic detection of diabetic retinopathy. Journal Français d'Ophtalmologie, 44(3), 420-440.

[12] Das, D., Biswas, S. K., & Bandyopadhyay, S. (2023). Detection of diabetic retinopathy using convolutional neural networks for feature extraction and classification (DRFEC). Multimedia tools and applications, 82(19), 29943-30001.

[13] Gundluru, N., Rajput, D. S., Lakshmanna, K., Kaluri, R., Shorfuzzaman, M., Uddin, M., & Rahman Khan, M. A. (2022). Enhancement of detection of diabetic retinopathy using Harris hawks optimization with deep learning model. Computational Intelligence and Neuroscience, 2022(1), 8512469.

[14] Li, F., Wang, Y., Xu, T., Dong, L., Yan, L., Jiang, M., ... & Zou, H. (2022). Deep learning-based automated detection for diabetic retinopathy and diabetic macular oedema in retinal fundus photographs. Eye, 36(7), 1433-1441.

[15] Malhi, A., Grewal, R., & Pannu, H. S. (2023). Detection and diabetic retinopathy grading using digital retinal images. International Journal of Intelligent Robotics and Applications, 7(2), 426-458.

[16] Elgafi, M., Sharafeldeen, A., Elnakib, A., Elgarayhi, A., Alghamdi, N. S., Sallah, M., & El-Baz, A. (2022). Detection of diabetic retinopathy using extracted 3D features from OCT images. Sensors, 22(20), 7833.

[17] Chaurasia, B. K., Raj, H., Rathour, S. S., & Singh, P. B. (2023). Transfer learning–driven ensemble model for detection of diabetic retinopathy disease. Medical & Biological Engineering & Computing, 61(8), 2033-2049.

[18] Lalithadevi, B., & Krishnaveni, S. (2022). Detection of diabetic retinopathy and related retinal disorders using fundus images based on deep learning and image processing techniques: A comprehensive review. Concurrency and Computation: Practice and Experience, 34(19), e7032.

[19] Nasir, N., Oswald, P., Alshaltone, O., Barneih, F., Al Shabi, M., & Al-Shammaa, A. (2022, February). Deep DR: detection of diabetic retinopathy using a convolutional neural network. In 2022 Advances in Science and Engineering Technology International Conferences (ASET) (pp. 1-5). IEEE.

[20] Ramkumar, S., & Sasi, G. (2021). Detection of diabetic retinopathy using OCT image. Materials Today: Proceedings, 47, 185-190.

[21] Albahli, S., Nazir, T., Irtaza, A., & Javed, A. (2021). Recognition and Detection of Diabetic Retinopathy Using Densenet-65 Based Faster-RCNN. Computers, Materials & Continua, 67(2).

[22] Sharma, A., Shinde, S., Shaikh, I. I., Vyas, M., & Rani, S. (2021, February). Machine learning approach for detection of diabetic retinopathy with improved pre-processing. In 2021 International conference on computing, communication, and intelligent systems (ICCCIS) (pp. 517-522). IEEE.

[23] Deshpande, A., & Pardhi, J. (2021). Automated detection of Diabetic Retinopathy using VGG-16 architecture. Int. Res. J. Eng. Technol, 8(3), 2936-2940.

[24] Daanouni, O., Cherradi, B., &Tmiri, A. (2021). Automatic detection of diabetic retinopathy using custom cnn and grad-cam. In Advances on Smart and Soft Computing: Proceedings of ICACIn 2020 (pp. 15-26). Springer Singapore.

[25] Albahli, S., & Ahmad Hassan Yar, G. N. (2022). Automated detection of diabetic retinopathy using custom convolutional neural network. Journal of X-Ray Science and Technology, 30(2), 275-291.

[26] Parthasharathi, G. U., Premnivas, R., & Jasmine, K. (2022). Diabetic retinopathy detection using machine learning. Journal of Innovative Image Processing, 4(1), 26-33.
[27] Lakshminarayanan, V., Kheradfallah, H., Sarkar, A., & Jothi Balaji, J. (2021). Automated detection and diagnosis of diabetic retinopathy: A comprehensive survey. Journal of imaging, 7(9), 165.